Athersys Stock News

Bank of America lowered shares of Athersys (NASDAQ:ATHX) from a buy rating to a neutral rating in a research note issued to investors on Friday, Price Targets.com reports. The firm currently has $1.25 price target on the biopharmaceutical companys stock. Separately, Zacks Investment Research lowered shares of Athersys from a buy rating to a hold []

Athersys, Inc. (NASDAQ:ATHX) Director Ismail Kola acquired 85,000 shares of Athersys stock in a transaction that occurred on Friday, November 19th. The stock was acquired at an average cost of $0.96 per share, with a total value of $81,600.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the []

Athersys Inc. (NASDAQ:ATHX) price on Friday, November 19, fall -17.27% below its previous days close as a downside momentum from buyers pushed the stocks value to $0.93. A look at the stocks price movement, the level at last check in todays session was $1.13, moving within a range at $1.12 and $1.185. The beta value Athersys Inc. (ATHX): At $0.93, Its Worth Your Attention Read More »

Athersys (NASDAQ:ATHX) was downgraded by Bank of America from a buy rating to a neutral rating in a research note issued on Friday, The Fly reports. Separately, Zacks Investment Research cut Athersys from a buy rating to a hold rating in a research note on Monday, October 18th. Athersys stock opened at $1.13 on Friday. []

Athersys (NASDAQ:ATHX) announced its earnings results on Sunday. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping the Zacks consensus estimate of ($0.08) by $0.01, MarketWatch Earnings reports. During the same quarter in the prior year, the company earned ($0.11) earnings per share. ATHX stock opened at $1.15 on Tuesday. The companys []

Athersys, Inc. (ATHX) CEO B.J. Lehmann on Q3 2021 Results - Earnings Call Transcript

CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Positive topline data for ARDS study announced and countdown begins to the release of pivotal stroke study data for MultiStem cell therapy.

The "Europe Soft Tissue Repair Market 2021-2028" report has been added to ResearchAndMarkets.com''s offering. The European soft tissue repair market is anticipated to exhibit growth with a CAGR of

DUBLIN--(BUSINESS WIRE)--The "Europe Soft Tissue Repair Market 2021-2028" report has been added to ResearchAndMarkets.com''s offering. The European soft tissue repair market is anticipated to exhibit growth with a CAGR of 5.81% over the projected years between 2021 and 2028. The United Kingdom, Germany, Italy, Russia, Spain, France, and Rest of Europe together form the market in this region. The rising prevalence of smokers in France is contributing to the growing spread of cardiovascular disord

Geode Capital Management LLC lifted its position in shares of Athersys, Inc. (NASDAQ:ATHX) by 12.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,454,380 shares of the biopharmaceutical companys stock after purchasing an additional 390,984 shares during the period. Geode Capital Management []

CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Athersys to Host Q3 Financial Results Call on November 15, 2021 at 4:30 pm ET.

Investors need to pay close attention to Athersys (ATHX) stock based on the movements in the options market lately.

Positive ARDS Results in Japan should lead to approval and revenues.

Athersys, Inc. (ATHX) CEO William Lehmann on Q2 2021 Results - Earnings Call Transcript

Shares of Athersys (NASDAQ:ATHX) increased in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were unchanged 0.00% over the past year to ($0.10), whic